To our knowledge, RHB-107 (formerly MESUPRON), a non-cytotoxic and orally administered 3-amidinophenylalanine-based inhibitor, developed by Heidelberg Pharma AG (formerly WILEX AG) and now licenced by RedHill Biopharma Ltd., is the only known drug candidate to target the uPA-pathway that has been effective in Phase II clinical trials for locally advanced non-resectable pancreatic cancer. Here, PLAU is linked to familial pancreatic carcinoma.